End-of-day quote
Korea S.E.
06:00:00 2024-06-06 pm EDT
|
5-day change
|
1st Jan Change
|
2,555
KRW
|
+12.06%
|
|
+10.37%
|
-22.22%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
317,282
|
279,086
|
279,845
|
230,799
|
73,111
|
Enterprise Value (EV)
1 |
248,288
|
221,538
|
236,944
|
182,513
|
56,475
|
P/E ratio
|
139
x
|
-14.4
x
|
-10.6
x
|
-5.52
x
|
-1.6
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
5,443,790
x
|
44,020,258
x
|
145,437,856
x
|
76,328,781
x
|
731,109,622
x
|
EV / Revenue
|
4,260,028
x
|
34,943,175
x
|
123,141,684
x
|
60,359,828
x
|
564,751,831
x
|
EV / EBITDA
|
232
x
|
-11.5
x
|
-9.11
x
|
-4.3
x
|
-1.45
x
|
EV / FCF
|
-9.48
x
|
-31.5
x
|
-25.1
x
|
-8.19
x
|
-3.39
x
|
FCF Yield
|
-10.5%
|
-3.17%
|
-3.98%
|
-12.2%
|
-29.5%
|
Price to Book
|
4.76
x
|
4.71
x
|
6.5
x
|
4.66
x
|
4.27
x
|
Nbr of stocks (in thousands)
|
16,583
|
19,181
|
19,707
|
19,896
|
22,256
|
Reference price
2 |
19,133
|
14,550
|
14,200
|
11,600
|
3,285
|
Announcement Date
|
3/11/20
|
3/22/21
|
3/17/22
|
3/15/23
|
3/18/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
|
-
|
58,283
|
6,340
|
1,924
|
3,024
|
100
|
EBITDA
1 |
-15,448
|
1,069
|
-19,220
|
-26,010
|
-42,423
|
-38,925
|
EBIT
1 |
-15,816
|
617.2
|
-19,578
|
-26,392
|
-43,501
|
-40,349
|
Operating Margin
|
-
|
1.06%
|
-308.81%
|
-1,371.6%
|
-1,438.66%
|
-40,349.43%
|
Earnings before Tax (EBT)
1 |
-40,728
|
7,226
|
-19,232
|
-26,278
|
-41,700
|
-42,455
|
Net income
1 |
-40,728
|
1,325
|
-19,232
|
-26,278
|
-41,700
|
-42,321
|
Net margin
|
-
|
2.27%
|
-303.35%
|
-1,365.7%
|
-1,379.08%
|
-42,321.05%
|
EPS
2 |
-6,927
|
137.2
|
-1,010
|
-1,345
|
-2,102
|
-2,059
|
Free Cash Flow
1 |
12,113
|
-26,181
|
-7,027
|
-9,435
|
-22,289
|
-16,679
|
FCF margin
|
-
|
-44.92%
|
-110.83%
|
-490.37%
|
-737.12%
|
-16,679.09%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/29/19
|
3/11/20
|
3/22/21
|
3/17/22
|
3/15/23
|
3/18/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
2,653
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
68,994
|
57,548
|
42,901
|
48,286
|
16,636
|
Leverage (Debt/EBITDA)
|
-0.1718
x
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
12,113
|
-26,181
|
-7,027
|
-9,435
|
-22,289
|
-16,679
|
ROE (net income / shareholders' equity)
|
180%
|
6.52%
|
-28.7%
|
-51.4%
|
-87.9%
|
-119%
|
ROA (Net income/ Total Assets)
|
-64.5%
|
0.84%
|
-17.1%
|
-29.9%
|
-50.3%
|
-53.6%
|
Assets
1 |
63,142
|
156,898
|
112,575
|
87,755
|
82,908
|
78,991
|
Book Value Per Share
2 |
-7,815
|
4,017
|
3,088
|
2,184
|
2,488
|
769.0
|
Cash Flow per Share
2 |
1,263
|
3,432
|
1,092
|
416.0
|
399.0
|
626.0
|
Capex
1 |
70.7
|
494
|
79.8
|
165
|
437
|
320
|
Capex / Sales
|
-
|
0.85%
|
1.26%
|
8.57%
|
14.45%
|
319.51%
|
Announcement Date
|
3/29/19
|
3/11/20
|
3/22/21
|
3/17/22
|
3/15/23
|
3/18/24
|
|
1st Jan change
|
Capi.
|
---|
| -22.22% | 45.38M | | +18.72% | 125B | | +14.19% | 108B | | -4.93% | 24.21B | | +3.23% | 22.78B | | -10.44% | 17.96B | | -41.74% | 16.43B | | -13.31% | 16.37B | | +2.44% | 13.58B | | +27.89% | 11.66B |
Bio Therapeutic Drugs
|